AstraZeneca PLC (NASDAQ:AZN) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company announced ...

Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.

Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.

By integrating foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods.

A new treatment option, Datroway (datopotamab deruxtecan or Dato-DXd), is now available for people with non-small cell lung ...

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA ...

Datroway has been cleared for use in adults with locally advanced or metastatic EGFR-mutated NSCLC who have previously received EGFR-directed therapy and platinum-based chemotherapy, making it the ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Datroway is the first and only TROP2-directed antibody-drug conjugate (ADC) approved in the U.S. for lung cancer. The drug is jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...